Sanjari Mojgan, Hadavizadeh Mohammad, Sadeghi Narges, Naghibzadeh-Tahami Ahmad
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Sci Rep. 2025 Jan 2;15(1):118. doi: 10.1038/s41598-024-83820-7.
The impact of blood glucose-lowering medications on weight has always been a topic of interest in the treatment of diabetic patients. This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes. This quasi-experimental study was performed on patients with prediabetes or type 2 diabetes with an HbA1c level up to 1% higher than the treatment target, and not using other blood glucose-lowering medications. Patients received 10 milligrams of Empagliflozin once daily for three months, and weight, BMI, waist circumference, and blood pressure were evaluated monthly. Forty-three patients (21 women and 22 men) enrolled. The average weight of patients decreased by 2.96 ± 1.96 kg (3.8%) (P < 0.001). BMI decreased by -1.10 ± 0.71 Kg/m (3.72%) (P < 0.001). The waist circumference of patients decreased by -3.23 ± 3.69 centimeters (P < 0.001). FPG decreased from 114.86 to 109.48 mg/dL (P < 0.001), and HbA1c decreased from 6.52% to 6.38% (P < 0.001). The weight change was more significant in men than women (-3.59 ± 1.74 vs. -2.30. ± 1.99), (P = 0.029). Weight reduction was greater in patients with GFR higher than 90 compared to GFR lower than 90 (-3.34. ± 2.00 vs. -2.16 ± 1.67) (P = 0.063). Also, no significant difference was observed in the weight, BMI, and waist circumference changes between different BMI groups (less than 25, 25 to 30, 30 to 35, and higher than 35). The trend of weight and BMI changes during the three-month empagliflozin treatment period was significant (P < 0.001) and didn't reach a plateau level after three months. The change in waist circumference was also significant, reaching a plateau level after one month (P < 0.001). There was no significant change in blood pressure. In conclusion the weight, BMI, and waist circumference of patients decreased following the administration of empagliflozin. Weight reduction was more pronounced in males than females and in patients with a GFR above 90 than those with a GFR below 90. Trial registration: This study was approved by the Research Deputy of Kerman University of Medical Sciences with tracking number 401,000,516, IRCT code: IRCT20090317001774N10, and ethical code: IR.KMU.AH.REC.1402.065 was approved by Research Ethics Committee of Afzalipour Hospital- Kerman University of Medical Sciences.
降糖药物对体重的影响一直是糖尿病患者治疗中备受关注的话题。本研究调查了恩格列净对糖尿病前期和2型糖尿病患者体重的影响。这项准实验性研究针对的是糖化血红蛋白（HbA1c）水平比治疗目标高1%以内、且未使用其他降糖药物的糖尿病前期或2型糖尿病患者。患者每天服用10毫克恩格列净，持续三个月，每月评估体重、体重指数（BMI）、腰围和血压。共有43名患者（21名女性和22名男性）入组。患者的平均体重下降了2.96±1.96千克（3.8%）（P<0.001）。BMI下降了-1.10±0.71千克/米（3.72%）（P<0.001）。患者的腰围下降了-3.23±3.69厘米（P<0.001）。空腹血糖（FPG）从114.86毫克/分升降至109.48毫克/分升（P<0.001），HbA1c从6.52%降至6.38%（P<0.001）。体重变化在男性中比女性更显著（-3.59±1.74 vs. -2.30±1.99），（P=0.029）。与估算肾小球滤过率（GFR）低于90的患者相比，GFR高于90的患者体重减轻更明显（-3.34±2.00 vs. -2.16±1.67）（P=0.063）。此外，不同BMI组（小于25、25至30、30至35以及高于35）之间的体重、BMI和腰围变化未观察到显著差异。在恩格列净治疗的三个月期间，体重和BMI变化趋势显著（P<0.001），三个月后未达到平稳水平。腰围变化也很显著，一个月后达到平稳水平（P<0.001）。血压没有显著变化。总之，服用恩格列净后患者的体重、BMI和腰围下降。男性比女性体重减轻更明显，GFR高于90者比GFR低于90者体重减轻更明显。试验注册：本研究经克尔曼医科大学研究副校长批准，追踪编号为401,000,516，伊朗临床试验注册中心（IRCT）代码：IRCT20090317001774N10，伦理代码：IR.KMU.AH.REC.1402.065，已获得克尔曼医科大学阿夫扎利普尔医院研究伦理委员会批准。
